Braveheart Bio, Inc. BRVE
Braveheart Bio, Inc. (Nasdaq: BRVE) is a cardio-renal-metabolic drug developer. Its lead program, BHB-1893, is in Phase 3 for Obstructive hypertrophic cardiomyopathy (oHCM) and non-obstructive HCM (nHCM). Its next catalyst on record is BHB-1893 (NOBLEHEART-HCM): Initiate global Phase 3 trial in nHCM (H1 2027).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: BHB-1893 (NOBLEHEART-HCM) — Initiate global Phase 3 trial in nHCM (H1 2027). 3 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| BHB-1893 (LIONHEART-HCM) | Obstructive HCM | small molecule | Phase 3 |
| BHB-1893 (NOBLEHEART-HCM) | Non-obstructive HCM | small molecule | Phase 2 |
| HRS-1893 (Hengrui, Greater China only) | Heart failure with preserved ejection fraction | small molecule | Phase 2 |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 cardio-renal-metabolic companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.